肝炎治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Hepatitis Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月21日 | 出版商:

Global Market Insights Inc. | 英文 231 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球肝炎治療市場估值達到 222 億美元，預計在預測期內複合年成長率為 3.5%。該市場的主要動力是乙型肝炎和丙型肝炎感染發病率的上升以及全球對這些疾病的認知不斷增強。抗病毒療法和免疫療法等治療方案的創新正在改善患者護理並促進市場擴張。此外，聚合酶鏈反應（PCR）檢測等診斷技術的進步改善了早期檢測，進一步刺激了對肝炎治療的需求。

整個肝炎治療行業根據疾病類型、治療類型、給藥途徑、最終用戶和地區進行分類。

市場根據疾病類型、治療類型、給藥途徑和最終用戶進行細分。在疾病類型中，丙型肝炎細分市場占主導地位，到 2023 年將達到 98 億美元。製藥公司正在大力投資研發，以提高藥物療效、縮短治療時間並盡量減少副作用。

在治療類型方面，由於肝炎感染盛行率不斷上升，2023年抗病毒藥物佔了61.4%的主要佔有率。這些療法對於治療肝炎至關重要，特別是對於 B 型和 C 型肝炎，它們可以減少病毒量並控制疾病進展。由於人們對該疾病的認知不斷提高以及早期診斷的重要性，新興市場對抗病毒藥物的需求也在增加。

就給藥途徑而言，由於其便利性和患者依從性高，口服給藥預計到 2032 年將達到 121 億美元。口服療法，特別是直接作用的抗病毒藥物，以更高的療效和更少的副作用徹底改變了肝炎治療。

在最終用戶類別中，包括醫院和專科診所在內的醫療保健提供者預計將以 3.5% 的複合年成長率成長。這些提供者在實施抗病毒治療、進行診斷和監測患者病情進展方面發揮關鍵作用。疫苗接種計劃和減少傷害服務等公共衛生措施也促進了這一領域的成長。

從地區來看，在抗病毒療法的進步和強大的醫療基礎設施的推動下，到 2032 年，北美地區的銷售額預計將達到 134 億美元。由於肝炎病例的增加和治療方案的不斷變化，歐洲，尤其是英國，正在經歷強勁的成長。在亞太地區，在早期檢測、獲得負擔得起的治療以及政府主導的肝炎管理計劃的支持下，市場預計將以 4.1% 的複合年成長率擴張。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Service Provider
Medication Manufacturers

簡介目錄

Product Code: 10910

The Global Hepatitis Treatment Market reached a valuation of USD 22.2 billion in 2023 and is expected to grow at a CAGR of 3.5% through the forecast period. The market is primarily driven by the rising incidence of hepatitis B and C infections and the growing global awareness surrounding these conditions. Innovations in treatment options, such as antiviral therapies and immunotherapies, are enhancing patient care and contributing to market expansion. Additionally, advancements in diagnostic technologies like polymerase chain reaction (PCR) testing have improved early detection, further fueling demand for hepatitis treatments.

The overall hepatitis treatment industry is segregated based on Disease Type, Treatment Type, Route of Administration, End-user, and Region.

The market is segmented based on disease type, treatment type, route of administration, and end-user. Among disease types, the hepatitis C segment dominated with USD 9.8 billion in 2023. Rising infection rates and advancements in antiviral treatments are propelling the growth of this segment. Pharmaceutical companies are heavily investing in R&D to enhance drug efficacy, reduce treatment durations, and minimize side effects.

In terms of treatment types, antiviral drugs captured a major share of 61.4% in 2023, driven by the growing prevalence of hepatitis infections. These therapies are crucial in managing hepatitis, particularly for types B and C, where they decrease the viral load and control disease progression. The demand for antiviral drugs is also increasing in emerging markets due to rising awareness of the disease and the importance of early diagnosis.

Regarding the route of administration, the oral segment is set to reach USD 12.1 billion by 2032, thanks to its convenience and high patient compliance. Oral therapeutics, especially direct-acting antivirals, have revolutionized hepatitis treatment with higher efficacy and fewer side effects.

In the end-user category, healthcare providers, including hospitals and specialty clinics, are expected to grow at a CAGR of 3.5%. These providers play a key role in administering antiviral therapies, conducting diagnostics, and monitoring patient progress. Public health initiatives, such as vaccination programs and harm reduction services, also contribute to this segment's growth.

Regionally, North America is projected to reach USD 13.4 billion by 2032, driven by advancements in antiviral therapies and a strong healthcare infrastructure. Europe, particularly the UK, is experiencing robust growth due to rising hepatitis cases and evolving treatment options. In Asia-Pacific, the market is expected to expand at a CAGR of 4.1%, supported by early detection, access to affordable therapies, and government-led hepatitis management programs.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of hepatitis infections
  - 3.2.1.2 Advancements in drug development
  - 3.2.1.3 Rising demand for combination therapies
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of medications
  - 3.2.2.2 Side effects and adverse reactions
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Hepatitis A
5.3 Hepatitis B
5.4 Hepatitis C
5.5 Other hepatitis types

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Anti-viral drugs
- 6.2.1 Nucleoside/nucleotide analogues
- 6.2.2 Polymerase inhibitors
- 6.2.3 Protease inhibitors
- 6.2.4 Other anti-viral drugs
6.3 Immune modulators (interferons)
6.4 Combination therapies
6.5 Liver transplant
6.6 Other treatment types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Parenteral

Chapter 8 Market Estimates and Forecast, By End-user, 2021-2032 ($ Mn)

8.1 Key trends
8.2 Healthcare providers
- 8.2.1 Hospitals
- 8.2.2 Specialty clinics
8.3 Patients
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

10.1 Service Provider
- 10.1.1 Barnes-Jewish Hospital
- 10.1.2 Bumrungrad International Hospital
- 10.1.3 Cedars-Sinai
- 10.1.4 Cleveland Clinic
- 10.1.5 Mayo Clinic
10.2 Medication Manufacturers
- 10.2.1 AbbVie Inc.
- 10.2.2 Biocon, Inc.
- 10.2.3 Bristol-Myers Squibb Company
- 10.2.4 Dynavax Technologies
- 10.2.5 F. Hoffmann-La Roche Ltd.
- 10.2.6 Gilead Sciences, Inc.
- 10.2.7 GlaxoSmithKline plc
- 10.2.8 Lupin Limited
- 10.2.9 Merck and Co., Inc.
- 10.2.10 Novartis AG